Where will we be in 12 months time?, page-254

@braggy this is a good point. Even for those insured the out of pocket expense (component) will still have an influence on uptake. It might also depend if the BOTANIX wants to offer an additional savings card (code) which could reduce it down to zero based on which insurance company one is insured with. The initial Drs recommendation (hyperhydrosis grading) (prescription) is crucial to having insurance sign off. After that repeats can be a formality.

However, considering the market size even accounting for those individuals the number potentially using the product presents a large market opportunity. Added to that the present side effects linked to the use of Obexza (mainly the oral dryness) presents a viable alternative, that customers might take on a level of out of pocket to use a convenient and effective treatment.

I think this is why they have stressed the discussions with insurance companies. If they can find a more attractive but still very profitable cost then this will end up a licence to print money.